Literature DB >> 29635134

The long non-coding RNA-DANCR exerts oncogenic functions in non-small cell lung cancer via miR-758-3p.

Sheng Wang1, Ming Jiang2.   

Abstract

Long non-coding RNAs (lncRNAs) have been demonstrated to be involved in the occurrence and progression of multiple cancers. In this study, we investigated the role of the lncRNA DANCR in the development of non-small cell lung cancer (NSCLC). First, we found that DANCR was markedly upregulated in NSCLC tumor tissues and cell lines compared with related normal controls. The ectopic expression of DANCR significantly increased the proliferation, migration and invasion of SPC-A1 and NCL-H1299 cells. Furthermore, we investigated whether DANCR regulates NSCLC tumor formation in vivo. Subsequently, we concluded that DANCR promotes NSCLC cell proliferation, migration and invasion by regulating the tumor suppressor miR-758-3p. These results indicated that the DANCR/miR-758-3p axis could be a potential target in the treatment of NSCLC.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cell growth; Invasion; LncRNA DANCR; miR-758-3p; non-small cell lung cancer

Mesh:

Substances:

Year:  2018        PMID: 29635134     DOI: 10.1016/j.biopha.2018.03.053

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  18 in total

1.  MicroRNA-758 inhibits cervical cancer cell proliferation and metastasis by targeting HMGB3 through the WNT/β-catenin signaling pathway.

Authors:  Tao Song; Xinghua Hou; Bing Lin
Journal:  Oncol Lett       Date:  2019-06-12       Impact factor: 2.967

Review 2.  Regulation of mTOR signaling by long non-coding RNA.

Authors:  Karam Aboudehen
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2019-11-18       Impact factor: 4.490

3.  LncRNA DANCR upregulates PI3K/AKT signaling through activating serine phosphorylation of RXRA.

Authors:  Jianming Tang; Guangsheng Zhong; Haibo Zhang; Bo Yu; Fangqiang Wei; Liming Luo; Yao Kang; Jianhui Wu; Jiaxiang Jiang; Yucheng Li; Shuqiang Wu; Yongshi Jia; Xiaodong Liang; Aihong Bi
Journal:  Cell Death Dis       Date:  2018-12-05       Impact factor: 8.469

4.  LncRNA DANCR contributes to tumor progression via targetting miR-216a-5p in breast cancer: lncRNA DANCR contributes to tumor progression.

Authors:  Weiyang Tao; Chunyang Wang; Bifa Zhu; Guoqiang Zhang; Da Pang
Journal:  Biosci Rep       Date:  2019-04-23       Impact factor: 3.840

5.  Long non-coding RNA DANCR promotes the progression of non-small-cell lung cancer by inhibiting p21 expression.

Authors:  Lanfang Guo; Jianmei Gu; Sinan Hou; Dabiao Liu; Mengjie Zhou; Tengjiang Hua; Jinye Zhang; Zhijun Ge; Jing Xu
Journal:  Onco Targets Ther       Date:  2018-12-21       Impact factor: 4.147

6.  Long noncoding RNA DANCR in various cancers: a meta-analysis and bioinformatics.

Authors:  Lihong Wang; Yalin Xie; Hui Fang; Xia Zhang; Huiyun Pan; Senxiang Yan
Journal:  Cancer Manag Res       Date:  2019-07-15       Impact factor: 3.989

7.  LncRNA DANCR-miR-758-3p-PAX6 Molecular Network Regulates Apoptosis and Autophagy of Breast Cancer Cells.

Authors:  Xian Hu Zhang; Bing Feng Li; Jie Ding; Lei Shi; Huo Ming Ren; Kui Liu; Chuan Cai Huang; Fu Xiao Ma; Xin Yao Wu
Journal:  Cancer Manag Res       Date:  2020-05-29       Impact factor: 3.989

8.  Identification of miR-758-3p as Potential Modulator of CBX5 Expression in Gastric Cancer.

Authors:  Jinxing Guo; Zichao Zhang; Lijie Pan; Yuanhang Zhou
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

9.  Long noncoding RNA DANCR regulates proliferation and migration by epigenetically silencing FBP1 in tumorigenesis of cholangiocarcinoma.

Authors:  Ni Wang; Chongguo Zhang; Wulin Wang; Jie Liu; Yang Yu; You Li; Mingjiong Zhang; Xianxiu Ge; Quanpeng Li; Lin Miao
Journal:  Cell Death Dis       Date:  2019-08-05       Impact factor: 8.469

Review 10.  Long Non-coding RNA DANCR as an Emerging Therapeutic Target in Human Cancers.

Authors:  Shi-Jia Jin; Ming-Zhu Jin; Bai-Rong Xia; Wei-Lin Jin
Journal:  Front Oncol       Date:  2019-11-15       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.